Pharmacogenomics and Personalized Medicine

Pharmacogenomics is one of the emerging approaches to precision medicine, tailoring drug selection and dosing to the patient’s genetic features. In recent years, several pharmacogenetic guidelines have been published by international scientific consortia, but the uptake in clinical practice is still poor. Many coordinated international efforts are ongoing in order to overcome the existing barriers to pharmacogenomic implementation. On the other hand, existing validated pharmacogenomic markers can explain only a minor part of the observed clinical variability in the therapeutic outcome. New investigational approaches are warranted, including the study of the pharmacogenomic role of the immune system genetics and of previously neglected rare genetic variants, reported to account for a large part of the inter-individual variability in drug metabolism. In this Special Issue, we collected a series of articles covering many aspects of pharmacogenomics. These include clinical implementation of pharmacogenomics in clinical practice, development of tools or infrastractures to support this process, research of new pharmacogenomics markers to increase drug efficacy and safety, and the impact of rare genetic variants in pharmacogenomics.

[1]  Munir Pirmohamed,et al.  Generating evidence for precision medicine: considerations made by the Ubiquitous Pharmacogenomics Consortium when designing and operationalizing the PREPARE study , 2020, Pharmacogenetics and genomics.

[2]  M. Relling,et al.  The Clinical Pharmacogenetics Implementation Consortium: 10 Years Later , 2019, Clinical pharmacology and therapeutics.

[3]  Munir Pirmohamed,et al.  Global Pharmacogenomics Within Precision Medicine: Challenges and Opportunities , 2019, Clinical pharmacology and therapeutics.

[4]  L. De Cecco,et al.  Focal Recurrent Copy Number Alterations Characterize Disease Relapse in High Grade Serous Ovarian Cancer Patients with Good Clinical Prognosis: A Pilot Study , 2019, Genes.

[5]  Yanjun Xu,et al.  Quantifying Risk Pathway Crosstalk Mediated by miRNA to Screen Precision drugs for Breast Cancer Patients , 2019, Genes.

[6]  H. Guchelaar,et al.  Pharmacist-Initiated Pre-Emptive Pharmacogenetic Panel Testing with Clinical Decision Support in Primary Care: Record of PGx Results and Real-World Impact , 2019, Genes.

[7]  C. Ross,et al.  Outcome Definition Influences the Relationship between Genetic Polymorphisms of ERCC1, ERCC2, SLC22A2 and Cisplatin Nephrotoxicity in Adult Testicular Cancer Patients , 2019, Genes.

[8]  S. Pounds,et al.  MicroRNAs Mediated Regulation of Expression of Nucleoside Analog Pathway Genes in Acute Myeloid Leukemia , 2019, Genes.

[9]  G. Toffoli,et al.  FARMAPRICE: A Pharmacogenetic Clinical Decision Support System for Precise and Cost-Effective Therapy , 2019, Genes.

[10]  A. Ventura,et al.  Azathioprine Biotransformation in Young Patients with Inflammatory Bowel Disease: Contribution of Glutathione-S Transferase M1 and A1 Variants , 2019, Genes.

[11]  J. C. Barrera,et al.  Pharmacogenetics in the Treatment of Cardiovascular Diseases and Its Current Progress Regarding Implementation in the Clinical Routine , 2019, Genes.

[12]  V. Gasic,et al.  Pharmacogenomic and Pharmacotranscriptomic Profiling of Childhood Acute Lymphoblastic Leukemia: Paving the Way to Personalized Treatment , 2019, Genes.

[13]  A. V. van Kuilenburg,et al.  Diagnostic and Therapeutic Strategies for Fluoropyrimidine Treatment of Patients Carrying Multiple DPYD Variants , 2018, Genes.

[14]  L. AL-Eitan,et al.  Impact of CYP2C9 and VKORC1 Polymorphisms on Warfarin Sensitivity and Responsiveness in Jordanian Cardiovascular Patients during the Initiation Therapy , 2018, Genes.